For instance, gallbladder cancer, which typically shows a limited response to anti-PD-L1 therapy, often expresses higher levels of HHLA2 than PD-L1, suggesting that targeting HHLA2 could be a viable therapeutic strategy. Here, CD274 is linked to gallbladder cancer.